EAM
PRQR icon

EverPoint Asset Management’s ProQR Therapeutics PRQR Stock Holding History

EverPoint Asset Management’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-128,235
Closed -$2.14M – 510
2015
Q2 		$2.14M Sell
128,235
-71,765
-36% -$1.35M 0.04% 373
2015
Q1 		$4.38M Buy
+200,000
New +$4.13M 0.08% 309

Other funds holding PRQR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM

EverPoint Asset Management's PRQR Position: Q3 2015 in Review

EverPoint Asset Management sold out of ProQR Therapeutics (PRQR) in Q3 2015, closing a stake of 128,235 shares — an estimated $2.14M sold.

EverPoint Asset Management first reported a position in PRQR in Q1 2015 and held it in 2 quarters. The position peaked at $4.38M in Q1 2015. 37 funds tracked by Wall St. Rank hold PRQR as of Q3 2015.

  • EverPoint Asset Management reported no remaining ProQR Therapeutics position as of Q3 2015 after selling out during the quarter.
  • EverPoint Asset Management sold 128,235 ProQR Therapeutics shares in Q3 2015, an estimated $2.14M.
  • EverPoint Asset Management first reported a position in ProQR Therapeutics in Q1 2015 and held it in 2 quarters.
  • EverPoint Asset Management's ProQR Therapeutics position peaked at $4.38M in Q1 2015.
  • 37 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q3 2015.

Based on EverPoint Asset Management's 13F filing for Q3 2015, filed 16 Nov 2015.